Royalty Pharma plc (RPRX) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à New York City, NY, United States. Le PDG actuel est Pablo Legorreta.
RPRX a date d'introduction en bourse 2020-06-16, 75 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $20.92B.
Royalty Pharma plc is a biopharmaceutical royalty company that identifies, evaluates, and acquires royalty streams from innovative drug therapies across the United States. The company collaborates with academic institutions, research hospitals, biotechnology companies, and pharmaceutical firms to fund biopharmaceutical innovation. Its diversified portfolio includes royalties on approximately 35 marketed therapies and 10 development-stage product candidates spanning therapeutic areas such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. Founded in 1996 and headquartered in New York, Royalty Pharma generates revenue through its ownership of royalty interests in marketed drugs while supporting the advancement of new treatments.
